@benedetta99a

DeSci projects raised $100 million in 2025, with platforms like VitaDAO funding $50 million in biotech research via tokenization. However, token economics raise concerns—80% of DeSci tokens, like VITA, rely on emission-based rewards, not real yield, per HashKey Capital. This mirrors 2023’s unsustainable models, with 50% of tokens down 40% due to oversupply. Only 20% of projects, like Molecule, tie tokens to IP-NFTs, generating $5 million in licensing revenue. Without utility—90% of token holders don’t participate in governance—value may erode 30% by 2026. DeSci’s $1 billion market could grow 20% if real yield models emerge, but speculative funding risks a 50% crash if tokenomics don’t align with scientific output.

0 reply

0 recast

0 reaction